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A single nucleotide polymorphism in the gene for FGFR4 ( Arg388) has been associated with progression in various types of human
cancer. Although fibroblast growth factors (FGFs) belong to the most important growth factors in melanoma, expression of FGF
receptor subtype 4 has not been investigated yet. In this study, the protein expression of this receptor was analysed in 137 melanoma
tissues of different progression stages by immunohistochemistry. FGFR4 protein was expressed in 45% of the specimens and
correlated with pTNM tumour stages (UICC, P¼0.023 and AJCC, P¼0.046), presence of microulceration (P¼0.009), tumour
vascularity (P¼0.001), metastases (P¼0.025), number of primary tumours (P¼0.022), overall survival (P¼0.047) and disease-free
survival (P¼0.024). Furthermore, FGFR4 Arg388 polymorphism was analysed in 185 melanoma patients by polymerase chain
reaction-restriction fragment length polymorphism (PCR-RFLP). The Arg388 allele was detected in 45% of the melanoma patients
and was significantly associated with tumour thickness (by Clark’s level of invasion (P¼0.004) and by Breslow in mm (P¼0.02)) and
the tumour subtype nodular melanoma (P¼0.002). However, there was no correlation of the FGFR4 Arg388 allele with overall and
disease-free survival. In conclusion, the Arg388 genotype and the protein expression of FGFR4 may be potential markers for
progression of melanoma.
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Melanoma is one of the most aggressive tumours, once meta-
stasised. The rising incidence makes this cancer an issue of ever
increasing clinical and economic importance and research interest
(Garland et al, 2003; Tucker and Goldstein, 2003; Berwick et al,
2005). The identification of new prognostic markers may help to
better distinguish low from high-risk disease apart from the
classical histopathologic and clinical criteria (Carlson et al, 2005)
and may offer new targets for therapy.
The mechanism by which normal melanocytes transform to
malignant melanoma cells is still poorly understood, but it is
known that growth factors and their corresponding receptors play
an important role in the progression of melanoma (Shih and
Herlyn, 1994; Krasagakis et al, 1995). One of the best characterised
activators for cell growth, proliferation, differentiation and
migration in melanoma is basic fibroblast growth factor (bFGF)
(Klagsbrun and Baird, 1991; Bikfalvi et al, 1997), a multifunctional
cytokine that interacts with four different types of high-affinity
receptors (FGFR1-4). These are members of a family of
transmembrane receptors with ligand-induced tyrosine kinase
activity. Basic fibroblast growth factor is highly mitogenic for
melanocytes and is provided by neighbouring keratinocytes and
fibroblasts in the skin (Halaban et al, 1988a,b; Root and Shipley,
1999). Especially in combination with ultraviolet radiation, bFGF
has been shown to act as a potent inductor of melanoma (Berking
et al, 2001). In contrast to melanocytes, bFGF can be produced by
nevus and melanoma cells and may act as an autocrine growth
factor through the FGF receptors (Halaban et al, 1987; Halaban
et al, 1988c; Albino et al, 1991; Scott et al, 1991; Reed et al, 1994;
al-Alousi et al, 1996a,b; Meier et al, 2003). It has been
demonstrated that melanoma cells cannot survive if bFGF or
FGFR1 are targeted (Wang and Becker, 1997; Graeven et al, 2001;
Valesky et al, 2002). Yayon et al (1997) demonstrated that direct
interference with the activity of FGFR1 suppressed cell prolifera-
tion and survival of melanoma possibly through the inactivation of
a Src-family kinase. To date bFGF/FGFR1 is the best characterised
growth factor/growth factor receptor coexpression pair that has
been found in primary and metastatic melanoma (Kaipainen et al,
1994; Wang and Becker, 1997). However, bFGF may also act
through the other FGF receptor subtypes, which have been
described in various human diseases and malignancies.
Genetic alterations, such as point mutations, have been
identified in FGFR genes and have been linked to developmental
defects as well as neoplastic degeneration (Balasubramanian et al,
2002). Mutations in the FGFR1 and FGFR2 genes have been shown
to cause craniosynostotic aberrations such as Apert-, Pfeiffer-,
Jackson-, Weiss- and Crouzon syndrome (Muenke and Schell,
1995). A single amino-acid exchange of a conserved glycine to
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sarginine in the transmembrane domain of FGFR3 has been found
in 90% of patients suffering from achondroplasia (Muenke and
Schell, 1995). Other mutations in the FGFR3 or FGFR2 genes have
been associated with bladder, cervical or colorectal cancer
(Cappellen et al, 1999; Jang et al, 2001).
Recently, Bange et al (2002) discovered a germline polymorph-
ism in the gene encoding for FGFR4. The single nucleotide
polymorphisms (SNP) results in a change of the amino-acid
sequence at codon 388 from glycine to arginine (Gly388 to
Arg388). It was demonstrated that FGFR4 Arg388 was not involved
in tumour initiation, as the FGFR4 alleles showed a similar
distribution in breast cancer patients and healthy controls and
appeared in approximately 50% of the human population.
However, the Arg388 isotype was significantly overrepresented in
the group of node-positive breast cancer patients with early relapse
but not associated with a shortened disease-free survival in node-
negative breast cancer (Bange et al, 2002). Recently, Streit et al
(2004) demonstrated an association between high expression of
FGFR4 Arg388 allele and poor clinical outcome in head and neck
squamous cell carcinoma (HNSCC). These findings were sup-
ported by independent groups with similar results in soft tissue
sarcoma, prostate cancer and lung adenocarcinoma (Morimoto
et al, 2003; Wang et al, 2004; Spinola et al, 2005).
In this study, the focus is on FGFR4 in melanoma analysing its
expression and different genotypes in relation with pathological
and clinical parameters.
MATERIALS AND METHODS
Tissue samples
Formalin-fixed and paraffin-embedded archival tissues of 198
primary melanomas were collected at the Department of
Dermatology of the Ludwig-Maximilian University of Munich,
Germany. All patients had a histopathologically confirmed
diagnosis of melanoma between 1993 and 1999. The median
follow-up was 59 months (female 54 months, male 59.5 months;
range 2–141 months). The cohort consisted of 93 female and 105
male patients with a median age of 65 years (female 68 years; range
26–92 years, male 62 years; range 23–93 years) at the date of
diagnosis. The selected cohort of patients included primary
melanomas with low tumour thickness followed by metastasis
and/or death of the patients after 5 years follow-up as well as
primary melanomas with high tumour thickness, but no metastasis
and/or death of the patients after 5 years. In all, 121 patients stayed
free of metastases (pTNM stage 1 and 2), 42 patients had local and
regional metastases (pTNM stage 3) and 35 patients had distant
metastases (pTNM stage 4). Patient characteristics and pTNM
tumour stages according to UICC (Union Internationale Contre le
Cancer) and AJCC (American Joint Committee on Cancer) are
summarised in Table 1.
Immunohistochemistry
Paraffin-embedded sections (5mm) were subjected to deparaffini-
sation in xylene and rehydrated in a graded series of isopropanol.
Antigen retrieval was achieved by microwave in citrate buffer, pH
6.0 (Chemicom IHC Select, Temecula, Canada) for FGFR4 and
Ki-67 and by Proteinase (P8038, SIGMA, Steinheim, Germany) for
CD-31. Blocking of unspecific bindings was done with FCS/Tris
20%. As primary antibodies were used: rabbit anti-human FGFR4
((C16): sc-124, Santa Cruz Biotechnology, Inc., Heidelberg,
Germany), mouse anti-human Ki-67 (M7187, DAKO, Glostrup,
Denmark) and mouse anti-human CD-31 (M0823, DAKO,
Glostrup, Denmark). They were incubated overnight at room
temperature. Secondary antibodies were mouse anti-rabbit (MAR)
antibody (M0737, DAKO, Glostrup, Denmark) and alkaline
phosphatase-conjugated rabbit anti-mouse (RAM) antibody
(Z0259, DAKO, Glostrup, Denmark) followed by alkaline phos-
phatase anti-alkaline phosphatase (APAAP, Mouse) antibody (D
0651, DAKO). Fast Red was used as substrate and Mayer’s
hematoxylin as counterstaining. Two investigators (DSM, CB)
read all tissue sections using a light microscope (Axilloskop,
Leica). Microvessel density (MVD) and microulcerations were
recorded in a blinded manner on HE-stained sections. Microvessel
density was estimated in the centre and at the edge of each tumour
and graded low, medium or high in comparison to the
surrounding tissue. Additionally, MVD was evaluated by staining
for CD-31 and counting a mean of five visual fields (range 2–10) at
 200 magnification. Likewise, the proliferation rate was evaluated
with the help of staining for Ki-67.
DNA extraction
Five to ten paraffin-embedded sections (10mm) were deparaffi-
nised with xylene and rehydrated in a graded series of ethanol. The
specimens were then treated with proteinase K (Roche, Mannheim,
Germany) in digestion buffer (Tris-Cl; EDTA; SDS10%; pH 8.5) for
36–72h at 551C. After incubation in phenol and chloroform:
isoamylalcohol (24:1) and repeated cycles of precipitation, sodium
acetate and 100% ethanol were added and incubated at  201C for
24h. After centrifugation at 41C for 30min, pellets were washed
with 70% ethanol and suspended in deionised H2O. Samples were
stored at 41C.
FGFR4 genotyping
The analysis of FGFR4 Arg388 was carried out as described
previously (Bange et al, 2002). The following primers were used:
50-GACCGCAGCAGCGCCGAGGCCAG-30 and 50-AGAGGGAAGAG
GGAGAGCTTCTG-30. Primers (2mM) and genomic DNA were
combined in a 25-ml total reaction volume using Ready-to-Go PCR
beads (Pharmacia, Uppsala, Sweden). After denaturing at 951C for
3min, the reaction mixture was subjected to 35 cycles of 45s at
951C and 45s at 721C followed by one cycle at 721C for 5min. The
168bp fragment was digested overnight with BstNI (NewEngland
BioLabs) according to the manufacturer’s instruction. Restriction
fragments were resolved on a 12% nondenaturing polyacrylamide
gel and DNA was visualised with ethidium bromide. The Arg388
allele was characterised by two distinctive fragments of 80 and
29bp, whereas a single distinctive band of 109bp was observed for
the Gly388 allele.
Statistical analysis
Statistical analyses were performed using the statistical packages
MedCalc (MedCalc Software, Belgium), WinStat (R. Fitch Software,
Staufen, Germany) and SPSS (Superior Performance Software
System, Munich, Germany). Association between different catego-
rical variables were assessed by Pearson’s w
2 test. Univariate
analyses of time to death (overall survival) or time to recurrence
(disease-free survival) were performed using the product-limit
procedure (Kaplan–Meier method) and compared using log-Rank
statistics, with date of histological diagnosis as the starting point. A
P-value of o0.05 was regarded significant.
RESULTS
FGFR4 protein expression in melanoma tissues
By immunohistochemical analysis, 137 different primary melano-
mas could be evaluated for protein expression of FGFR4. In 45%
(61/137) of the tumours, FGFR4 was detected with varying staining
intensities (Figure 1E) in the cytoplasm of the melanoma cells
(Table 2). Strong reactivity for FGFR4 was found in 4 cases (7%;
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sFigure 1C), while 51 tumours (83%) displayed intermediate
(Figure 1D) and 6 (10%) only minimal staining intensities. Positive
staining was found throughout the tumours and was not different
at the infiltrative front or at the margin of ulcerations and necrosis.
Besides melanoma cells keratinocytes, fibroblasts, nerves, smooth
muscle cells, sweat glands and sebaceous glands were stained for
FGFR4, but not melanocytes. The number of FGFR4-expressing
melanoma cells per tumour was 100% in 20 cases, 50–99% in 10
cases, 10–49% in 21 cases and 1–9% in 10 cases (Table 2).
Association of FGFR4 expression with survival of patients
The status of FGFR4 protein expression was correlated with
clinical and pathological data (Table 2). There was no obvious
correlation between staining intensity and tumour characteristics
or patient outcome. Thus, for the following statistical analyses
tumours with FGFR4 expression were combined in one group,
regardless of the number of positively stained cells and the staining
intensity.
No correlation was found between protein expression of FGFR4
and gender, age at date of diagnosis or localisation of the tumour.
There was also no association with tumour thickness and
histological subtype.
With respect to the UICC and AJCC TNM staging systems a
significant association was found between FGFR4 protein expres-
sion and pTNM tumour stages III and IV as opposed to tumour
stages I and II (UICC, P¼0.023 and AJCC P¼0.046). Furthermore,
microscopic ulceration of the tumours, which is a negative
prognostic criteria according to the revised AJCC classification,
was significantly correlated with positive expression of FGFR4
(P¼0.009). In addition, 31 of 56 (55%) melanoma patients with
metastatic disease showed FGFR4 protein expression (P¼0.025).
When comparing FGFR4 protein expression and number of
primary tumours, 22 (65%) of 34 patients with more than one
melanoma were positive for FGFR4 (P¼0.022). Furthermore,
Kaplan–Meier survival analysis for a mean follow-up time of 72
months revealed that expression of FGFR4 in melanoma was
associated with reduced overall survival (P¼0.047; Figure 2A) as
well as reduced disease-free survival (P¼0.024; Figure 2B) of the
respective patients.
Association of FGFR4 protein expression with microvessel
density and proliferation rate
Tumour vascularity was evaluated on 137 melanoma tissues and
compared to the expression of FGFR4. There was a significant
correlation between a high MVD and positive expression of FGFR4
(Table 2). This was confirmed by the higher amount of CD-31-
positive vessels within the tumours with positive FGFR4 protein
expression (Figure 1G) as opposed to FGFR4-negative tumours
(Table 2).
Table 1 Patient characteristics
Patients n¼198
Sex
Male 105 (53%)
Female 93 (47%)
Median age at diagnosis (years) 65 (range 23–93)
Date of diagnosis 1993–1999
pTNM UICC staging (n¼198) 0: Tis, N0, M0 0 (0%)
pT1: p0.75mm Ia: pT1, N0, M0 57 (29%)
pT2: 0.76–1.5mm Ib: pT2, N0, M0 20 (10%)
pT3a: 1.51–3.0mm or level IV IIa: pT3, N0, M0 34 (17%)
pT3b: 3.01–4.0mm or level IV IIb: pT4a, N0, M0 10 (5%)
pT4a: 44.0mm or level V IIIa: pT4a/pT4b, N1, M0 29 (15%)
pT4b: Satellite met(s) within 2cm from tumour IIIb: any pT, N1/N2, M0 13 (6%)
N1: Lymph node met(s) p3cm IV: any pT, any N, M1 35 (18%)
N2a: Lymph node met(s) 43cm
N2b: In-transit met(s)
N2c: Lymph node met(s) 43cm and in-transit met(s)
M: Distant met(s)
pTNM AJJC staging (n¼139) 0: Tis, N0, M0 0 (0%)
T1: p1.0mm Ia: T1a, N0, M0 39 (28%)
a: without ulceration; b: with ulceration or level IV or V Ib: T1b, T2a, N0, M0 18 (13%)
T2: 1.01–2.0mm IIa: T2b, T3a, N0, M0 12 (8%)
a: without ulceration; b: with ulceration IIb: T3b, T4a, N0, M0 13 (9%)
T3: 2.01–4.0mm IIc: T4b, N0, M0 5 (4%)
a: without ulceration; b: with ulceration IIIa: T1-4a, N1a/N2a, M0 11 (7%)
T4: 44.0mm IIIb: T1-4b, N1a/N2a, N1b/N2b 18 (13%)
a: without ulceration; b: with ulceration T1-4a/b, N2c, M0
N1: One lymph node IIIc: T1-4b, N1b/N2b/N3, M0 5 (4%)
a: micrometastasis; b: macrometastasis IV: any T, any N, M1 22 (16%)
N2: 2–3 lymph nodes
a: micrometastasis; b: macrometastasis
c: in-transit met(s)/satellite(s) without metastatic lymph nodes
N3: X4 lymph nodes, satellite(s) and metastatic lymph node(s)
M1: Distant met(s)
Median follow-up time (months) 59 (range 2–141)
Abbreviations: AJCC, American Joint Committee on Cancer; met(s), metastases; pTNM, tumour, lymph node and distant metastasis status; UICC, Union Internationale Contre le
Cancer.
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sSimilarly, the proliferation marker Ki-67 was increased in
FGFR4-positive tumours (Figure 1H) compared to FGFR4-negative
tumours (Table 2). The Ki-67-positive cells were mainly localised
to the infiltrative front of the tumours.
FGFR4 genotype distribution in patients with melanoma
and association with clinicopathological parameters
Genotype analysis of the Gly388 allele and the Arg388 allele of
FGFR4 was performed in 185 melanomas by polymerase chain
reaction-restriction fragment length polymorphism (PCR-RFLP).
Gly/Gly, Gly/Arg and Arg/Arg genotypes were detected in 101
(55%), 69 (37%) and 15(8%) cases, respectively.
The Arg388 genotype of FGFR4 was compared with clinical and
pathological variables (Table 3). For statistical analysis, patients
homozygous or heterozygous for the Arg388 allele were combined
into one group.
Regarding the UICC and AJCC TNM staging systems and the
Arg388 polymorphism of FGFR4, no significant association could
be seen. There was also no correlation of the Arg388 genotype with
ulceration, microvessel density and proliferation (Ki-67). Further
clinical variables like gender, age at diagnosis and tumour
D
F E
H
C
A B
G
Figure 1 Immunohistochemical analysis of FGFR4, CD-31 and Ki-67 in primary melanoma tissues. (A) No expression of FGFR4 in a tumour nest (arrows)
of a superficial spreading melanoma (SSM). (B) Negative control of A after preincubation of the FGFR4 antibody with a blocking peptide. (C and D)
Expression of FGFR4 (red) in a nodular malignant melanoma (NMM) with high intensity (C) and in an SSM with intermediate intensity (D). (E) Expression of
FGFR4 in an NMM with areas of high intensity (arrow) and intermediate intensity (arrowhead). (F) H&E stained section of E.( G) Expression of CD-31 in
vessels (red) in an FGFR4-positive NMM. (H) Expression of Ki-67 (red) in proliferating melanoma cells of an FGFR4-positive SSM. Scale bar, 100mm.
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sTable 2 FGFR4 protein expression and clinical/pathological variables
FGFR4 expression Yes (%) No (%) P-value
Patients n¼137 n¼61 (45) n¼76 (55)
Median age (years) 70 62
Age at diagnosis (years)
p55 14 (23) 25 (33) NS
455 47 (77) 51 (67)
Sex
Male 33 (24) 42 (31) NS
Female 28 (20) 34 (25)
Localisation of tumour
Extremities 29 (21) 55 (40) NS
Trunk, head/neck 27 (20) 26 (19)
Staining intensity
Minimal 6 (10) NS
Intermediate 51 (83)
Strong 4 (7)
Positively stained cells per tumour
1–9% 10 (16) NS
10–49% 21 (34)
50–99% 10 (16)
100% 20 (34)
Microvessel density (n¼137)
Low 24 (18) 57 (42) 0.001
Medium 21 (15) 12 (9)
High 15 (11) 8 (6)
CD-31 (mean
a; n¼17) 44 28
Ki-67 (mean
b; n¼17) 24 14.5
pTNM UICC staging (n¼137)
Ia 15 (11) 23 (17) NS
Ib 4 (3) 11 (8) (0.023 when stages III+
IIa 8 (6) 12 (9)
IIb 3 (2) 5 (4) IV compared to I+II)
IIIa 11 (8) 12 (9)
IIIb 5 (4) 5 (4)
IV 15 (11) 8 (6)
pTNM AJCC staging (n¼137)
Ia 13 (9) 24 (18) NS
Ib 6 (4) 10 (7) (0.046 when stages
III+IV compared to I+II)
IIa 3 (2) 8 (6)
IIb 5 (4) 8 (6)
IIc 3 (2) 2 (1)
IIIa 5 (4) 6 (4)
IIIb 8 (6) 9 (7)
IIIc 3 (2) 2 (1)
IV 14 (10) 8 (6)
Tumour thickness Breslow
p1mm 27 (20) 32 (23) NS
41mm 34 (25) 44 (32)
Clark level
I0 0 N S
II 14 (10) 14 (10)
III 18 (13) 28 (20)
IV 26 (19) 30 (22)
V 3 (2) 4 (3)
Ulceration (n¼137)
Yes 27 (20) 18 (13) 0.009
No 33 (24) 59 (43)
No. of primary tumours
1 39 (28) 64 (47) 0.022
41 22 (16) 12 (9)
Table 2 (Continued)
FGFR4 expression Yes (%) No (%) P-value
Metastasis
Yes 31 (23) 25 (18) 0.025
No 30 (22) 51 (37)
No. of metastases
1 13 (23) 12 (22) NS
41 18 (32) 13 (23)
Subtype of metastasis
Local 11 (36) 12 (48) NS
Regional 5 (16) 5 (20)
Distant 15 (48) 8 (32)
Tumour subtype
SSM 30 (22) 37 (27) NS
NMM 25 (18) 25 (18)
Others 6 (5) 14 (10)
Abbreviations: AJCC, American Joint Committee on Cancer; NMM, nodular
malignant melanoma; No., number; NS, not significant; pTNM, tumour, lymph node
and distant metastasis status; SSM, superficial spreading melanoma; UICC, Union
Internationale Contre le Cancer.
aVessels per visual field.
bCells per visual field.
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Figure 2 Kaplan–Meier survival curves of patients with positive FGFR4
protein expression vs no FGFR4 protein expression in melanomas. End
point was (A) death or (B) relapse/metastases. FGFR4 protein expression
is linked with progressive disease.
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Arg388. No correlation of the Arg388 allele was detected with the
number of tumours per patient and the presence, number or type
of metastases.
However, there was a strong correlation between the presence of
at least one FGFR4 Arg388 allele and tumour thickness according
to Clark’s level of invasion IV and V as opposed to I, II and III
(P¼0.004) and to Breslow’s thickness (p1mm vs 41mm;
P¼0.02). When comparing the two most common histological
subtypes with each other, namely nodular malignant melanoma
(NMM), which represents the more invasive type, and superficial
spreading melanoma (SSM), 41 patients (60%) with NMM were
carriers of the FGFR4 Arg388 polymorphism (P¼0.002), whereas
only 27 patients (40%) with NMM had the Gly388 genotype.
DISCUSSION
Under physiological conditions, the activity and the cellular signals
of regulated tyrosine kinases (RTKs) are tightly controlled. A
dysfunction of these control mechanisms, for example, by an
aberrant expression of the RTK/ligand system or genetic altera-
tions, can result in a deregulated tyrosine kinase activity. Such
alterations are frequently linked to cancer and other hyperproli-
ferative or developmental disorders. In order to validate the
influence of FGFR4 and its Arg388 polymorphism in melanoma, a
large patient cohort with long-term follow-up of up to 141 months
was evaluated for FGFR4 protein expression in addition to the
FGFR4 genotype. The present study demonstrates an association
between FGFR4 in melanoma and clinical and histopathologic
parameters indicative of progression.
FGFR4 was expressed in 45% of 137 primary melanomas with
different intensities. High expression of FGFR4 has been described
already for breast cancer (Lehtola et al, 1992; Jaakkola et al, 1993),
pancreatic cancer (Leung et al, 1994) and renal cell carcinoma
(Takahashi et al, 1999). The cytoplasmic staining of the FGFR4 in
melanoma cells is in agreement with other publications investigat-
ing the expression for FGFR4 in other types of cancer (Gowardhan
et al, 2005; Mawrin et al, 2005). In contrast to FGFR1, no nuclear
staining could be observed for FGFR4 (Maher, 1996; Stachowiak
et al, 1997).
Comparing the expression with clinical data of melanoma
patients there was a significant correlation between FGFR4 protein
expression and pTNM stage according to UICC and AJCC
classification. The majority of early-stage melanoma did not
express FGFR4 in contrast to advanced-stage melanomas. Con-
sistent with these results an association between ulceration of
melanoma and FGFR4 protein expression was found, linking
FGFR4 protein expression with worse prognosis as has been shown
for ulcerations (Balch et al, 2000). These results suggest that
FGFR4 protein expression may be a prognostic marker for worse
Table 3 FGFR4 Arg388 genotype and clinical/pathological variables
FGFR4 allele G/G (%) G/R (%) R/R (%) P-value
Patients n¼185 n¼101 n¼69 n¼15
Median age (years) 68 64 55
Age at diagnosis
p55 28 (28) 19 (28) 8 (53) NS
455 73 (72) 50 (72) 7 (47)
Sex
Male 53 (29) 33 (18) 12 (6) NS
Female 48 (26) 36 (19) 3 (2)
Localisation of tumour
Extremities 64 (35) 49 (26) 5 (3) NS
Trunk, head/neck 37 (20) 20 (11) 10 (5)
Microvessel density (n¼139)
Low 45 (32) 33 (24) 7 (5) NS
Medium 15 (11) 12 (9) 4 (3)
High 12 (9) 10 (7) 1 (1)
CD-31 (mean
a; n¼17) 38 30 26
Ki-67 (mean
b; n¼17) 18 14 41
pTNM UICC staging (n¼185)
Ia 32 (16) 19 (10) 3 (2) NS
Ib 11 (6) 5 (3) 2 (1)
IIa 13 (7) 17 (9) 3 (2)
IIb 6 (3) 4 (2) 0 (0)
IIIa 14 (7) 11 (6) 2 (1)
IIIb 4 (2) 6 (3) 1 (1)
IV 21 (11) 7 (4) 4 (2)
pTNM AJCC staging (n¼139)
Ia 21 (15) 15 (11) 3 (2) NS
Ib 13 (9) 4 (3) 1 (1)
IIa 4 (3) 7 (5) 1 (1)
IIb 6 (4) 5 (4) 2 (1)
IIc 2 (1) 3 (2) 0 (0)
IIIa 4 (3) 5 (4) 2 (1)
IIIb 10 (7) 7 (5) 1 (1)
IIIc 0 (0) 3 (2) 0 (0)
IV 14 (10) 4 (3) 2 (1)
Tumour thickness Breslow
p1mm 50 (27) 26 (14) 4 (2) 0.02
41mm 51 (28) 43 (23) 11 (6)
Clark level
I 0 (0) 0 (0) 0 (0) NS
II 24 (12) 17 (9) 2 (1) (0.004 when
III 39 (20) 10 (5) 6 (3) levels IV+V
IV 37 (19) 36 (18) 5 (3) compared to
V 1 (1) 6 (3) 2 (1) II+III)
Ulceration (n¼139)
Yes 23 (17) 19 (14) 3 (2) NS
No 51 (37) 34 (24) 9 (6)
No. of primary tumours
1 75 (41) 55 (30) 14 (7) NS
41 26 (14) 14 (7) 1 (1)
Metastasis
Yes 39 (21) 24 (13) 7 (4) NS
No 62 (34) 45 (24) 8 (4)
No. of metastases
1 19 (27) 7 (10) 3 (4) NS
41 20 (29) 17 (24) 4 (6)
Table 3 (Continued)
FGFR4 allele G/G (%) G/R (%) R/R (%) P-value
Type of metastasis
Local 14 (36) 11 (46) 2 (29) NS
Regional 4 (10) 6 (25) 1 (14)
Distant 21 (54) 7 (29) 4 (57)
Tumour type
SSM 56 (30) 26 (14) 5 (3) 0.002
NMM 27 (15) 32 (17) 9 (5)
Others 18 (10) 11 (6) 1 (1)
AJCC, American Joint Committee on Cancer; NMM, nodular malignant melanoma;
No., number; NS, not significant; pTNM, tumour, lymph node and distant metastasis
status; SSM, superficial spreading melanoma; UICC, Union Internationale Contre le
Cancer; .
aVessels per visual field.
bCells per visual field.
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that FGFR4 was significantly overrepresented in the group of
melanoma patients with metastases. Moreover, a significant
association between FGFR4 protein expression and microvessel
density was observed and an increased number of proliferating
Ki-67-positive melanoma cells was found at the edges and at the
infiltrating front of FGFR4-postive tumours. The presence of
FGFR4 may facilitate the proliferative and angiogenic effects of
bFGF and thus confer an increased metastatic potential to the
melanoma cells (Rak and Kerbel, 1997; Wang and Becker, 1997;
Compagni et al, 2000; Straume and Akslen, 2002). It has been
demonstrated before that increased tumour vascularity plays a
decisive role in the prognosis of melanoma patients (Kashani-
Sabet et al, 2002).
Our data lead to the conclusion that FGFR4 protein expression
is linked with tumour progression. This hypothesis is further
supported by the analysis of patient’s outcome in relation to
FGFR4 expression by Kaplan–Meier method revealing a correla-
tion between FGFR4 and poor survival rates. Based upon our
results of this experimental study, it would be interesting to
conduct a new investigation on a representative cohort of
melanoma patients in order to determine, in a multivariate
analysis, the impact of FGFR4 on prognosis of melanoma patients
in comparison to other known prognostic factors.
Furthermore, patients with FGFR4-expressing tumours had
more often additional melanomas in the past. This may hint to
a role of FGFR4 in melanoma development, even though the
mechanism is unknown.
Regarding the genotypes of FGFR4 in melanoma patients, 55%
(101/185) had a homozygous Gly allele, while 45% (84/185) showed
at least one Arg388 allele. A similar distribution of the Gly388 and
Arg388 alleles was reported for breast cancer patients (Bange et al,
2002).
Notwithstanding the molecular mechanisms by which the
FGFR4 Arg388 polymorphism leads to a more aggressive clinical
phenotype is not completely understood. However, it has been
shown that cancer cells ectopically expressing FGFR4 Arg388
possessed increased cell motility as well as invasiveness (Bange
et al, 2002; Wang et al, 2004). This is in agreement with our
observations that the Arg388 allele was predominantly found in
nodular melanoma, which is characterised by vertical growth and
increased risk for metastasis compared to SSM. In accordance with
this, the Arg388 genotype was also associated with tumour
thickness by Clark’s level and by Breslow. On the other hand, we
could not find any correlation between the Arg388 genotype and
decreased survival rates of patients. Thus, the FGFR4 Arg388
genotype may be used as an additional risk factor for tumour
progression with respect to invasion; however, it does not seem to
be a good prognostic factor for disease outcome. It remains to
be speculated if a larger cohort of patients or a longer follow-up
period would change these results.
In accordance with previous studies, no correlation was found
between the genotype and the protein expression of FGFR4 (Streit
et al, 2004).
In conclusion, the previously observed genotype-dependent
difference in disease progression suggests that FGFR4 Arg388 as a
marker for tumour progression in different cancers can only partly
be demonstrated in melanoma. Nevertheless, independently from
this specific polymorphism, FGFR4 seems to play an important
role in melanoma considering the high expression rates in
advanced tumours and the positive correlation with worse clinical
outcome.
ACKNOWLEDGEMENTS
We thank Erika Sander and Ursula Na ¨gele for excellent technical
assistance. This work was supported by the Curt-Bohnewand-
Fonds (to CB) and the Deutsche Forschungsgemeinschaft (BE
2189/2-1 to CB).
REFERENCES
Albino AP, Davis BM, Nanus DM (1991) Induction of growth factor RNA
expression in human malignant melanoma: markers of transformation.
Cancer Res 51(18): 4815–4820
al-Alousi S, Barnhill R, Blessing K, Barksdale S (1996a) The prognostic
significance of basic fibroblast growth factor in cutaneous malignant
melanoma. J Cutan Pathol 23(6): 506–510
al-Alousi S, Carlson JA, Blessing K, Cook M, Karaoli T, Barnhill RL (1996b)
Expression of basic fibroblast growth factor in desmoplastic melanoma.
J Cutan Pathol 23(2): 118–125
Balasubramanian SP, Brown NJ, Reed MW (2002) Role of genetic
polymorphisms in tumour angiogenesis. Br J Cancer 87(10): 1057–1065
Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID,
Houghton Jr A, Kirkwood MD, Mihm MF, Morton DL, Reintgen D, Ross
MI, Sober A, Soong SJ, Thompsom JA, Thompson JF, Gershenwald JE,
McMasters KM (2000) A new American Joint Committee on Cancer
staging system for cutaneous melanoma. Cancer 88(6): 1484–1491
Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M,
Knyazeva T, Muller S, Gartner S, Sures I, Wang H, Imyanitov E, Ha ¨ring
HU, Knayzev P, Iacobelli S, Ho ¨fler H, Ullrich A (2002) Cancer
progression and tumor cell motility are associated with the FGFR4
Arg(388) allele. Cancer Res 62(3): 840–847
Berking C, Takemoto R, Satyamoorthy K, Elenitsas R, Herlyn M (2001)
Basic fibroblast growth factor and ultraviolet B transform melanocytes in
human skin. Am J Pathol 158(3): 943–953
Berwick M, Armstrong BK, Ben-Porat L, Fine J, Kricker A, Eberle C,
Barnhill R (2005) Sun exposure and mortality from melanoma. J Natl
Cancer Inst 97(3): 195–199
Bikfalvi A, Klein S, Pintucci G, Rifkin DB (1997) Biological roles of
fibroblast growth factor-2. Endocr Rev 18(1): 26–45
Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau
X, Chopin D, Thiery JP, Radvanyi F (1999) Frequent activating mutations
of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23(1):
18–20
Carlson JA, Ross JS, Slominski A, Linette G, Mysliborski J, Hill J, Miham Jr
M (2005) Molecular diagnostics in melanoma. J Am Acad Dermatol
52(5): 743–775
Compagni A, Wilgenbus P, Impagnatiello MA, Cotten M, Christofori G
(2000) Fibroblast growth factors are required for efficient tumor
angiogenesis. Cancer Res 60(24): 7163–7169
Garland CF, Garland FC, Gorham ED (2003) Epidemiologic evidence for
different roles of ultraviolet A and B radiation in melanoma mortality
rates. Ann Epidemiol 13(6): 395–404
Gowardhan B, Douglas DA, Mathers ME, McKie AB, McCracken SR,
Robson CN, Leung HY (2005) Evaluation of the fibroblast growth factor
system as a potential target for therapy in human prostate cancer. Br J
Cancer 92(2): 320–327
Graeven U, Rodeck U, Karpinski S, Jost M, Philippou S, Schmiegel W
(2001) Modulation of angiogenesis and tumorigenicity of human
melanocytic cells by vascular endothelial growth factor and basic
fibroblast growth factor. Cancer Res 61(19): 7282–7290
Halaban R, Ghosh S, Baird A (1987) bFGF is the putative natural growth
factor for human melanocytes. In vitro Cell Dev Biol 23(1): 47–52
Halaban R, Kwon BS, Ghosh S, Delli Bovi P, Baird A (1988b) bFGF as an
autocrine growth factor for human melanomas. Oncogene Res 3(2): 177–186
Halaban R, Langdon R, Birchall N, Cuono C, Baird A, Scott G, Moellmann
G, McGuire J (1988a) Basic fibroblast growth factor from human
keratinocytes is a natural mitogen for melanocytes. J Cell Biol 107(4):
1611–1619
Halaban R, Langdon R, Birchall N, Cuono C, Baird A, Scott G, Moellmann
G, McGuire J (1988c) Paracrine stimulation of melanocytes by
keratinocytes through basic fibroblast growth factor. Ann NY Acad Sci
548: 180–190
FGFR4 Arg388 allele correlates with tumour thickness
S Streit et al
1885
British Journal of Cancer (2006) 94(12), 1879–1886 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sJaakkola S, Salmikangas P, Nylund S, Partanen J, Armstrong E, Pyrhonen S,
Lehtovirta P, Nevanlinna H (1993) Amplification of fgfr4 gene in human
breast and gynecological cancers. Int J Cancer 54(3): 378–382
Jang JH, Shin KH, Park JG (2001) Mutations in fibroblast growth factor
receptor 2 and fibroblast growth factor receptor 3 genes associated with
human gastric and colorectal cancers. Cancer Res 61(9): 3541–3543
Kaipainen A, Vlaykova T, Hatva E, Bohling T, Jekunen A, Pyrhonen S,
Alitalo K (1994) Enhanced expression of the tie receptor tyrosine kinase
mesenger RNA in the vascular endothelium of metastatic melanomas.
Cancer Res 54(24): 6571–6577
Kashani-Sabet M, Sagebiel RW, Ferreira CM, Nosrati M, Miller III JR (2002)
Tumor vascularity in the prognostic assessment of primary cutaneous
melanoma. J Clin Oncol 20(7): 1826–1831
Klagsbrun M, Baird A (1991) A dual receptor system is required for basic
fibroblast growth factor activity. Cell 67(2): 229–231
Krasagakis K, Garbe C, Zouboulis CC, Orfanos CE (1995) Growth control of
melanoma cells and melanocytes by cytokines. Recent Results Cancer Res
139: 169–182
Lehtola L, Partanen J, Sistonen L, Korhonen J, Warri A, Harkonen P, Clarke
R, Alitalo K (1992) Analysis of tyrosine kinase mRNAs including four
FGF receptor mRNAs expressed in MCF-7 breast-cancer cells. Int J
Cancer 50(4): 598–603
Leung HY, Gullick WJ, Lemoine NR (1994) Expression and functional
activity of fibroblast growth factors and their receptors in human
pancreatic cancer. Int J Cancer 59(5): 667–675
Maher PA (1996) Identification and characterization of a novel, intra-
cellular isoform of fibroblast growth factor receptor-1(FGFR-1). J Cell
Physiol 169(2): 380–390
Mawrin C, Kirches E, Diete S, Wiedemann FR, Schneider T, Firsching R,
Kropf S, Bogerts B, Vorwerk CK, Kru ¨ger S, Dietzmann K (2005) Analysis
of a single nucleotide polymorphism in codon 388 of the FGFR4 gene in
malignant gliomas. Cancer Lett xx: 1–7, in press
Meier F, Caroli U, Satyamoorthy K, Schittek B, Bauer J, Berking C, Moller
H, Maczey E, Rassner G, Herlyn M, Garbe C (2003) Fibroblast growth
factor-2 but not Mel-CAM and/or beta3 integrin promotes progression of
melanocytes to melanoma. Exp Dermatol 12(3): 296–306
Morimoto Y, Ozaki T, Ouchida M, Umehara N, Ohata N, Yoshida A,
Shimizu K, Inoue H (2003) Single nucleotide polymorphism in fibroblast
growth factor receptor 4 at codon 388 is associated with prognosis in
high-grade soft tissue sarcoma. Cancer 98(10): 2245–2250
Muenke M, Schell U (1995) Fibroblast-growth-factor receptor mutations in
human skeletal disorders. Trends Genet 11(8): 308–313
Rak J, Kerbel RS (1997) bFGF and tumor angiogenesis – back in the
limelight? Nat Med 3(10): 1083–1084
Reed JA, McNutt NS, Albino AP (1994) Differential expression of basic
fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by
in situ hybridisation. Implications for tumor progression. Am J Pathol
144(2): 329–336
Root LL, Shipley GD (1999) Human dermal fibroblasts express multiple
bFGF and aFGF proteins. In vitro Cell Dev Biol 27A(10): 815–822
Scott G, Stoler M, Sarkar S, Halaban R (1991) Localization of basic
fibroblast growth factor mRNA in melanocytic lesions by in situ
hybridization. J Invest Dermatol 96(3): 318–322
Shih IM, Herlyn M (1994) Autocrine and paracrine roles for growth factors
in melanoma. In vivo 8(1): 113–123
Spinola M, Leoni V, Pignatiello C, Conti B, Ravagnani F, Pastorino U,
Dragani TA (2005) Functional FGFR4 Gly388Arg polymorphism
predicts prognosis in lung adenocarcinoma patients. J Clin Oncol
23(29): 7307–7311
Stachowiak EK, Maher PA, Tucholski J, Mordechai E, Joy A, Moffett J,
Coons S, Stachowiak MK (1997) Nuclear accumulation of fibroblast
growth factor receptors in human glial cells – association with cell
proliferation. Oncogene 14(18): 2201–2211
Straume O, Akslen LA (2002) Importance of vascular phenotype by basic
fibroblast growth factor, and influence of the angiogenic factors basic
fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-
A1/EphA2 on melanoma progression. Am J Pathol 160(3): 1009–1019
Streit S, Bange J, Fichtner A, Ihrler S, Issing W, Ullrich A (2004)
Involvement of the FGFR4 Arg388 allele in head and neck squamous cell
carcinoma. Int J Cancer 111(2): 213–217
Takahashi A, Sasaki H, Kim SJ, Kakizoe T, Miyao N, Sugimura T, Terada M,
Tsukamoto T (1999) Identification of receptor genes in renal cell
carcinoma associated with angiogenesis by differential hybridization
technique. Biochem Biophys Res Commun 257(3): 855–859
Tucker MA, Goldstein AM (2003) Melanoma etiology: where are we?
Oncogene 22: 3042–3052
Valesky M, Spang AJ, Fisher GW, Farkas DL, Becker D (2002) Noninvasive
dynamic fluorescence imaging of human melanomas reveals that
targeted inhibition of bFGF or FGFR-1 in melanoma cells blocks tumor
growth by apoptosis. Mol Med 8(2): 103–112
Wang J, Stockton DW, Ittmann M (2004) The fibroblast growth factor
receptor-4 Arg388 allele is associated with prostate cancer initiation and
progression. Clin Cancer Res 10(18 Part 1): 6169–6178
Wang Y, Becker D (1997) Antisense targeting of basic fibroblast growth
factor and fibroblast growth factor receptor-1 in human melanomas
blocks intratumoral angiogenesis and tumor growth. Nat Med 3(8):
887–893
Yayon A, Ma YS, Safran M, Klagsbrun M, Halaban R (1997) Suppression of
autocrine cell proliferation and tumorigenesis of human melanoma cells
and fibroblast growth factor transformed fibroblasts by a kinase-
deficient FGF receptor 1: evidence for the involvement of Src-family
kinases. Oncogene 14(25): 2999–3009
FGFR4 Arg388 allele correlates with tumour thickness
S Streit et al
1886
British Journal of Cancer (2006) 94(12), 1879–1886 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s